Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: Potential for detecting an at-Alzheimer's risk metabolic phenotype

Neurobiology of Aging

Volumn 40, Issue , 2016, Pages 155-163

  Rettberg, Jamaica R ^a   Dang, Ha ^b   Hodis, Howard N ^a,b   Henderson, Victor W ^c   St John, Jan A ^b   Mack, Wendy J ^b   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Biomarker; Cognitive aging; Hormone therapy; Menopause; Metabolism

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ESTRADIOL;

ALZHEIMER DISEASE; ARTICLE; CLUSTER ANALYSIS; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EXECUTIVE FUNCTION; FEMALE; GLOBAL COGNITION; HORMONAL THERAPY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LONGITUDINAL STUDY; METABOLIC DISORDER; METABOLIC RATE; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; VERBAL MEMORY; AGED; COGNITIVE DYSFUNCTION; MEMORY; METABOLISM; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

AGED; ALZHEIMER DISEASE; BIOMARKERS; COGNITION; COGNITIVE DYSFUNCTION; COHORT STUDIES; ESTRADIOL; EXECUTIVE FUNCTION; FEMALE; HUMANS; MEMORY; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84960469694     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.01.011     Document Type: Article

References (37)

1. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 2014, 10:e47-e92. Alzheimer's Association.
2. Barnes L.L., Bennett D.A. Alzheimer's disease in African Americans: risk factors and challenges for the future. Health Aff. 2014, 33:580-586.
3. Bonds D.E., Lasser N., Qi L., Brzyski R., Caan B., Heiss G., Limacher M.C., Liu J.H., Mason E., Oberman A., O'Sullivan M.J., Phillips L.S., Prineas R.J., Tinker L. The effect of conjugated equine oestrogen on diabetes incidence: the Women's health initiative randomised trial. Diabetologia 2006, 49:459-468.
4. Brinton R.D., Yao J., Yin F., Mack W.J., Cadenas E. Perimenopause as a neurological transition state. Nat. Rev. Endocrinol. 2015, 11:393-405.
5. Carrillo M.C., Brashear H.R., Logovinsky V., Ryan J.M., Feldman H.H., Siemers E.R., Abushakra S., Hartley D.M., Petersen R.C., Khachaturian A.S., Sperling R.A. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement. 2013, 9:123-131.e1.
6. Carvalho J.O., Tommet D., Crane P.K., Thomas M.L., Claxton A., Habeck C., Manly J.J., Romero H.R. Deconstructing racial differences: the effects of quality of education and cerebrovascular risk factors. J. Gerontol. B Psychol. Sci. Soc. Sci. 2015, 70:545-556.
7. Cheng G., Huang C., Deng H., Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 2012, 42:484-491.
8. Espeland M.A., Miller M.E., Goveas J.S., Hogan P.E., Coker L.H., Williamson J., Naughton M., Resnick S.M. Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women's health initiative study of cognitive aging. J. Womens Health (Larchmt) 2011, 20:1435-1443. Whisca Study Group.
9. Fitten L.J., Ortiz F., Fairbanks L., Bartzokis G., Lu P., Klein E., Coppola G., Ringman J. Younger age of dementia diagnosis in a Hispanic population in southern California. Int. J. Geriatr. Psychiatry 2014, 29:586-593.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
11. Gottesman R.F., Schneider A.L., Albert M., Alonso A., Bandeen-Roche K., Coker L., Coresh J., Knopman D., Power M.C., Rawlings A., Sharrett A.R., Wruck L.M., Mosley T.H. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014, 71:1218-1227.
12. Henderson V.W., Brinton R.D. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog. Brain Res. 2010, 182:77-96.
13. Henderson V.W., St John J.A., Hodis H.N., McCleary C.A., Stanczyk F.Z., Karim R., Shoupe D., Kono N., Dustin L., Allayee H., Mack W.J. Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20290-20295.
14. Hodis H.N., Mack W.J., Shoupe D., Azen S.P., Stanczyk F.Z., Hwang-Levine J., Budoff M.J., Henderson V.W. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 2015, 22:391-401.
15. Holmans P., Hamshere M., Hollingworth P., Rice F., Tunstall N., Jones S., Moore P., Wavrant DeVrieze F., Myers A., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., O'Donovan M., Jones L., Hardy J., Goate A., Lovestone S., Owen M., Williams J. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 135B:24-32.
16. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
17. Karim R., Stanczyk F.Z., Brinton R.D., Rettberg J., Hodis H.N., Mack W.J. Association of endogenous sex hormones with adipokines and ghrelin in postmenopausal women. J. Clin. Endocrinol. Metab. 2015, 100:508-515.
18. Kenna H., Hoeft F., Kelley R., Wroolie T., DeMuth B., Reiss A., Rasgon N. Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol. Aging 2013, 34:641-649.
19. Kenney M.C., Chwa M., Atilano S.R., Falatoonzadeh P., Ramirez C., Malik D., Tarek M., Del Carpio J.C., Nesburn A.B., Boyer D.S., Kuppermann B.D., Vawter M.P., Jazwinski S.M., Miceli M.V., Wallace D.C., Udar N. Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: implications for population susceptibility to diseases. Biochim. Biophys. Acta 2014, 1842:208-219.
20. Kivipelto M., Helkala E.L., Laakso M.P., Hänninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322:1447-1451.
21. Margolis K.L., Bonds D.E., Rodabough R.J., Tinker L., Phillips L.S., Allen C., Bassford T., Burke G., Torrens J., Howard B.V. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004, 47:1175-1187. Women's Health Initiative Investigators.
22. Mayeda E.R., Haan M.N., Kanaya A.M., Yaffe K., Neuhaus J. Type 2 diabetes and 10-year risk of dementia and cognitive impairment among older Mexican Americans. Diabetes Care 2013, 36:2600-2606.
23. Norton S., Matthews F.E., Barnes D.E., Yaffe K., Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014, 13:788-794.
24. O'Bryant S.E., Xiao G., Edwards M., Devous M., Gupta V.B., Martins R., Zhang F., Barber R. Biomarkers of Alzheimer's disease among Mexican Americans. J. Alzheimers Dis. 2013, 34:841-849. Texas Alzheimer's Research and Care Consortium (TARCC).
25. Pani L.N., Korenda L., Meigs J.B., Driver C., Chamany S., Fox C.S., Sullivan L., D'Agostino R.B., Nathan D.M. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008, 31:1991-1996.
26. Rawlings A.M., Sharrett A.R., Schneider A.L., Coresh J., Albert M., Couper D., Griswold M., Gottesman R.F., Wagenknecht L.E., Windham B.G., Selvin E. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann. Intern. Med. 2014, 161:785-793.
27. Rettberg J.R., Yao J., Brinton R.D. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front. Neuroendocrinol. 2014, 35:8-30.
28. Roberts R.O., Knopman D.S., Przybelski S.A., Mielke M.M., Kantarci K., Preboske G.M., Senjem M.L., Pankratz V.S., Geda Y.E., Boeve B.F., Ivnik R.J., Rocca W.A., Petersen R.C., Jack C.R. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 2014, 82:1132-1141.
29. Seshadri S., Wolf P.A., Beiser A., Au R., McNulty K., White R., D'Agostino R.B. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 1997, 49:1498-1504.
30. Sheikh N., Sharma S. Impact of ethnicity on cardiac adaptation to exercise. Nat. Rev. Cardiol. 2014, 11:198-217.
31. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
32. The Writing Group for the PEPI Trial, Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995, 273:199-208.
33. Wharton W., Gleason C.E., Dowling N.M., Carlsson C.M., Brinton E.A., Santoro M.N., Neal-Perry G., Taylor H., Naftolin F., Lobo R.A., Merriam G., Manson J.E., Cedars M.I., Miller V.M., Black D.M., Budoff M., Hodis H.N., Harman S.M., Asthana S. The KEEPS-cognitive and affective study: baseline associations between vascular risk factors and cognition. J. Alzheimers Dis. 2014, 40:331-341.
34. Whitmer R.A., Sidney S., Selby J., Johnston S.C., Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
35. Yao J., Rettberg J.R., Klosinski L.P., Cadenas E., Brinton R.D. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Aspects Med. 2011, 32:247-257.
36. Yin F., Yao J., Sancheti H., Feng T., Melcangi R.C., Morgan T.E., Finch C.E., Pike C.J., Mack W.J., Cadenas E., Brinton R.D. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiol. Aging 2015, 36:2282-2295.
37. Zeki Al Hazzouri A., Haan M.N., Whitmer R.A., Yaffe K., Neuhaus J. Central obesity, leptin and cognitive decline: the Sacramento Area Latino Study on Aging. Dement. Geriatr. Cogn. Disord. 2012, 33:400-409.